190 related articles for article (PubMed ID: 27091407)
21. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.
Lesterhuis WJ; de Vries IJ; Schuurhuis DH; Boullart AC; Jacobs JF; de Boer AJ; Scharenborg NM; Brouwer HM; van de Rakt MW; Figdor CG; Ruers TJ; Adema GJ; Punt CJ
Ann Oncol; 2006 Jun; 17(6):974-80. PubMed ID: 16600979
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Das R; Teitelbaum A; Garrison J; Kashala O; Chatterjee SK; Bhattacharya-Chatterjee M
J Clin Oncol; 1999 Sep; 17(9):2889-5. PubMed ID: 10561367
[TBL] [Abstract][Full Text] [Related]
24. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
25. A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer.
Lynch KT; Squeo GC; Kane WJ; Meneveau MO; Petroni G; Olson WC; Chianese-Bullock KA; Slingluff CL; Foley EF; Friel CM
Int J Cancer; 2022 Jan; 150(1):164-173. PubMed ID: 34480368
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
27. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
28. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
29.
Chen Y; Xue SA; Behboudi S; Mohammad GH; Pereira SP; Morris EC
Clin Cancer Res; 2017 Oct; 23(20):6178-6189. PubMed ID: 28710313
[No Abstract] [Full Text] [Related]
30. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
31. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
33. Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells.
Matera L; Beltramo E; Martinuzzi E; Buttiglieri S
Clin Exp Immunol; 2004 Aug; 137(2):320-8. PubMed ID: 15270849
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
35. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
Correale P; Aquino A; Giuliani A; Pellegrini M; Micheli L; Cusi MG; Nencini C; Petrioli R; Prete SP; De Vecchis L; Turriziani M; Giorgi G; Bonmassar E; Francini G
Int J Cancer; 2003 Apr; 104(4):437-45. PubMed ID: 12584740
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ
J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415
[TBL] [Abstract][Full Text] [Related]
37. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice.
Niethammer AG; Primus FJ; Xiang R; Dolman CS; Ruehlmann JM; Ba Y; Gillies SD; Reisfeld RA
Vaccine; 2001 Nov; 20(3-4):421-9. PubMed ID: 11672905
[TBL] [Abstract][Full Text] [Related]
38. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
39. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
